Coffee and the risk of hepatocellular carcinoma and chronic liver disease: A systematic review and meta-analysis of prospective studies

European Journal of Cancer Prevention

Volumn 26, Issue 5, 2017, Pages 368-377

  Bravi, Francesca ^a   Tavani, Alessandra ^a   Bosetti, Cristina ^a   Boffetta, Paolo ^b   La Vecchia, Carlo ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

chronic liver disease; coffee; liver cancer; meta analysis; prospective studies

Indexed keywords

CANCER RISK; CHRONIC LIVER DISEASE; COFFEE; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; CHRONIC DISEASE; COMPARATIVE STUDY; LIVER CIRRHOSIS; LIVER TUMOR; PHYSIOLOGY;

CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COFFEE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84964285857     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000252     Document Type: Review

References (47)

1. Bamia C, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K, et al. (2015). Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer 136: 1899-1908.
2. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. (2007). Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 46: 827-839.
3. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, et al. (2007). Coffee drinking and hepatocellular carcinoma risk: a meta-Analysis. Hepatology 46: 430-435.
4. Bravi F, Bosetti C, Tavani A, la Vecchia C. (2009). Coffee drinking and hepatocellular carcinoma: an update. Hepatology 50: 1317-1318.
5. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. (2013). Coffee reduces risk for hepatocellular carcinoma: an updated meta-Analysis. Clin Gastroenterol Hepatol 11: 1413-1421.
6. Cavin C, Holzhauser D, Constable A, Huggett AC, Schilter B. (1998). The coffeespecific diterpenes cafestol and kahweol protect against aflatoxin B1-induced genotoxicity through a dual mechanism. Carcinogenesis 19: 1369-1375.
7. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B. (2002). Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 40: 1155-1163.
8. Chuang SC, La Vecchia C, Boffetta P. (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286: 9-14.
9. DerSimonian R, Laird N. (1986). Meta-Analysis in clinical trials. Control Clin Trials 7: 177-188.
10. Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. (2014). Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-Analysis. Diabetes Care 37: 569-586.
11. Egger M, Davey Smith G, Schneider M, Minder C. (1997). Bias in meta-Analysis detected by a simple, graphical test. BMJ 315: 629-634.
12. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386.
13. Ferraroni M, Tavani A, Decarli A, Franceschi S, Parpinel M, Negri E, et al. (2004). Reproducibility and validity of coffee and tea consumption in Italy. Eur J Clin Nutr 58: 674-680.
14. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, et al. (2009). Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 50: 1360-1369.
15. Goh GB, Chow WC, Wang R, Yuan JM, Koh WP. (2014). Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology 60: 661-669.
16. Greenland S, Longnecker MP. (1992). Methods for trend estimation from summarized dose-response data, with applications to meta-Analysis. Am J Epidemiol 135: 1301-1309.
17. Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a meta-Analysis. Stat Med 21: 1539-1558.
18. Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, et al. (2008). Joint effects of coffee consumption and serum gammaglutamyltransferase on the risk of liver cancer. Hepatology 48: 129-136.
19. Inoue M, Yoshimi I, Sobue T, Tsugane S. (2005). Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 97: 293-300.
20. Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M, et al. (2009). Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 18: 1746-1753.
21. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. (2011). Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 22: 503-510.
22. Klatsky AL, Armstrong MA. (1992). Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 136: 1248-1257.
23. Klatsky AL, Armstrong MA, Friedman GD. (1993). Coffee, tea, and mortality. Ann Epidemiol 3: 375-381.
24. Klatsky AL, Morton C, Udaltsova N, Friedman GD. (2006). Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 166: 1190-1195.
25. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, et al. (2004). Dietary habits and risk of death due to hepatocellular carcinoma in a large scale cohort study in Japan. Univariate analysis of JACC study data. Kurume Med J 51: 141-149.
26. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, et al. (2005). Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 93: 607-610.
27. La Vecchia C, Negri E, Cavalieri d?Oro L, Franceschi S. (1998). Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 7: 315-320.
28. Lai GY, Weinstein SJ, Albanes D, Taylor PR, McGlynn KA, Virtamo J, et al. (2013). The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 109: 1344-1351.
29. Loftfield E, Shiels MS, Graubard BI, Katki HA, Chaturvedi AK, Trabert B, et al. (2015). Associations of coffee drinking with systemic immune and inflammatory markers. Cancer Epidemiol Biomarkers Prev 24: 1052-1060.
30. London TW, McGlynn KA. (2006). Liver cancer. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. 3rd ed. New York, NY: Oxford University Press. pp. 763-786.
31. Majer BJ, Hofer E, Cavin C, Lhoste E, Uhl M, Glatt HR, et al. (2005). Coffee diterpenes prevent the genotoxic effects of 2-Amino-1-methyl-6-phenylimidazo [4, 5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem Toxicol 43: 433-441.
32. Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, et al. (2010). Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 51: 201-209.
33. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. (2009). Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med 151: 264-269.
34. Nakanishi N, Nakamura K, Nakajima K, Suzuki K, Tatara K. (2000). Coffee consumption and decreased serum gamma-glutamyltransferase: a study of middle-Aged Japanese men. Eur J Epidemiol 16: 419-423.
35. Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, et al. (2008). Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 17: 846-854.
36. Petrick JL, Freedman ND, Graubard BI, Sahasrabuddhe VV, Lai GY, Alavanja MC, et al. (2015). Coffee consumption and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma by sex: the liver cancer pooling project. Cancer Epidemiol Biomarkers Prev 24: 1398-1406.
37. Ruhl CE, Everhart JE. (2005). Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129: 1928-1936.
38. Ruhl CE, Everhart JE. (2005). Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 128: 24-32.
39. Saab S, Mallam D, Cox GA 2nd, Tong MJ. (2014). Impact of coffee on liver diseases: a systematic review. Liver Int 34: 495-504.
40. Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, le Marchand L, Henderson BE. (2015). Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 148: 118-125.
41. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, et al. (2005). Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 116: 150-154.
42. Tanaka T, Nishikawa A, Shima H, Sugie S, Shinoda T, Yoshimi N, et al. (1990). Inhibitory effects of chlorogenic acid, reserpine, polyprenoic acid (E-5166), or coffee on hepatocarcinogenesis in rats and hamsters. Basic Life Sci 52: 429-440.
43. Thornton A, Lee P. (2000). Publication bias in meta-Analysis: its causes and consequences. J Clin Epidemiol 53: 207-216.
44. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. (2011). Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 103: 1686-1695.
45. Tverdal A, Skurtveit S. (2003). Coffee intake and mortality from liver cirrhosis. Ann Epidemiol 13: 419-423.
46. World Cancer Research Fund. (2015). International systematic literature review. The association between food, nutrition, and physical activity and the risk of liver cancer. Washington, DC: World Cancer Research Fund/American Institute for Cancer Research
47. World Health Organization. (2008). Burden of disease: death estimates for 2004 by cause for WHO member states. Geneva, Switzerland: WHO